MPT Product Development Database

This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Product TypeDelivery RouteDelivery MethodDevelopment Stage
       
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
       
Key Word Search   
       

30 product(s) found



Tenofovir IVR

MPT in Development

Active Ingredient:
  • Tenofovir (TFV)
  • Developer:
  • CONRAD
  • Funding:
  • U.S. Agency for International Development (USAID)
  • Development Stage:
    Clinical – Phase 1 Trial (C1)
    Delivery Route & Method:
    Topical - Intravaginal Ring (IVR)
    Mechanism of Action:
    nucleoside analogue reverse transcriptase inhibitor (NRTI)
    Product Indications:
  • HIV
  • HSV-2
  • Description:
    Polyurethane, reservoir ring. For 90 days. First Phase I completed (CONRAD-128). Expanded Phase I trial (MTN-038) ongoing and will be completed late 2019. A first-in-kind study to evaluate MPT IVRs in Africa is also ongoing (CDC Kisumu Combined Ring Study/CONRAD B17-44) and will be completed late 2019.
    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    © Copyright 2019, Public Health Institute / IMPT Secretariat. All rights reserved.

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, an organization dedicated to advancing the comprehensive sexual and reproductive health of women and girls worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
    PEPFAR USAID PHI CAMI Health